Skip to main content
. Author manuscript; available in PMC: 2021 Jul 1.
Published in final edited form as: Muscle Nerve. 2020 Feb 24;61(5):587–594. doi: 10.1002/mus.26833

TABLE 1.

Demographic and disease characteristics of the participants

Parameter Mean (SD) or n (%)
Age, mean (SD) 55.4 (10.5)
BMI, mean (SD) 29.8 (6.9)
Stage of breast cancer, n (%) Stage I 8 (40%)
Stage II 5 (25%)
Stage III 2 (10%)
Stage IV 5 (25%)
Prior radiation therapy, n (%) 10 (50%)
Prior surgery for breast cancer, n (%) 19 (95%)
Prior hormone therapy for breast cancer, n (%) 8 (40%)
Prior lines of systemic cancer therapy, median (IQR) 1(1–3)
Most recent taxane, n (%) Paclitaxel 10 (50%)
Docetaxel 8 (40%)
Nab-paclitaxel 2 (10%)
Cumulative taxane dose, mg/m2, mean (SD) 817.3 (414.9)
Months since last taxane dose, median (IQR) 3.8 (1.0–6.1)
Relevant comorbidities, n (%) Diabetes, no end-organ damage 4 (20%)
Hypothyroidism 3 (15%)
Depression 3 (15%)
Alcoholism 1(5%)
Cerebovascular disease 1 (5%)
Vitamin B12 deficiency 1 (5%)

IQR, interquartile range; Nab, nanoparticle albumin–bound.